In addition, other combination strategies of PARPi plus other-than-PARPDDR inhibitors (e.g., CHK1 and WEE1 inhibitors) are also under evaluation in HNSCC [51]. This evidence concerns the gene WEE1 and head and neck squamous cell carcinoma.